However, FLT3 inhibitors such as gilteritinib have led to better outcomes for AML patients by reducing patient risk and mortality, enhancing proinflammatory cytokine production by NK cells, and the possibility of combination therapies to combat tumor resistance to treatment better than previously available treatments. The gene discussed is FLT3; the disease is acute myeloid leukemia.